Who is sponsoring NCT03548701?

NCT03548701 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT03548701?

Interventions in NCT03548701: Thromboelastometry testing.

What condition does NCT03548701 study?

NCT03548701 studies Pregnancy Trimester, First, Abortion, Threatened.

Is NCT03548701 still recruiting?

NCT03548701 is currently completed. Last updated 1 June 2020.

Last reviewed 2020-06-01 · How we verify

NCT03548701: TEMPURA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thromboelastometry Prediction Utility for Risk of Abortion

Completed Last updated 1 June 2020

What this trial tests

trial testing Thromboelastometry testing in Pregnancy Trimester, First in 98 participants. Completed in 15 May 2019.

Timeline

4 June 2018

Primary endpoint
15 May 2019

15 May 2019

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Status	Completed
Study type	OBSERVATIONAL
Enrollment	98
Start date	4 June 2018
Primary completion	15 May 2019
Estimated completion	15 May 2019
Sites	1 location across United States

Drugs / interventions tested

Thromboelastometry testing

Conditions studied

Pregnancy Trimester, First — all drugs for Pregnancy Trimester, First →
Abortion, Threatened — all drugs for Abortion, Threatened →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 18 to 65, female only, with Pregnancy Trimester, First or Abortion, Threatened. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will use thromboelastometry in ED patients with vaginal bleeding, as well as healthy pregnant controls, to determine if abnormal results are associated with the presence of vaginal bleeding as well as later complications during pregnancy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Case-control study of clotting differences using ROTEM testing in pregnant patients with early vaginal bleeding.
Maher P, Katz D, Afzal O, Nyamu S, et al · · 2025 · PMID 39579743 · DOI 10.1016/j.ejogrb.2024.11.019

Verify or expand the search:

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03548701 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 1 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03548701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing